Clinical Co Operation Group Immunotherapy at the Helmholtz Institute Munich

München, Germany

Clinical Co Operation Group Immunotherapy at the Helmholtz Institute Munich

München, Germany
SEARCH FILTERS
Time filter
Source Type

Lichtenegger F.S.,Ludwig Maximilians University of Munich | Schnorfeil F.M.,Ludwig Maximilians University of Munich | Schnorfeil F.M.,Clinical Co operation Group Immunotherapy at the Helmholtz Institute Munich | Hiddemann W.,Ludwig Maximilians University of Munich | And 3 more authors.
Immunotherapy | Year: 2013

The prognosis of acute myeloid leukemia, particularly when associated with adverse chromosomal or molecular aberrations, is poor due to a high relapse rate after induction chemotherapy. Postremission therapy for elimination of minimal residual disease remains a major challenge. Allogeneic hematopoietic stem cell transplantation has proven to provide a potent antileukemic effect. Novel strategies are needed for patients ineligible for this treatment. Here current immunotherapeutic concepts in acute myeloid leukemia in a nonallogeneic hematopoietic stem cell transplantation setting are reviewed. Data gathered with different monoclonal antibodies are discussed. Adoptive transfer of NK and T cells is reviewed, including evolving data on T-cell engineering. Results of systemic cytokine administration and of therapeutic vaccinations with peptides, modified leukemic cells and dendritic cells are presented. One particular focus of this review is the integration of currently running clinical trials. Recent immunotherapeutic studies have been encouraging and further interesting results are to be expected. © 2013 Future Medicine Ltd.


Lichtenegger F.S.,Ludwig Maximilians University of Munich | Lichtenegger F.S.,Clinical Co Operation Group Immunotherapy at the Helmholtz Institute Munich | Lorenz R.,Ludwig Maximilians University of Munich | Lorenz R.,Clinical Co Operation Group Immunotherapy at the Helmholtz Institute Munich | And 6 more authors.
Leukemia Research | Year: 2014

Cyclic cytotoxic maintenance therapy can be applied to patients with AML in post-remission. We studied the immune status of AML patients in complete remission and the effect of maintenance therapy on different immune cell populations. Patients in complete remission had reduced NK, TH and Treg counts and a reduced NK activation capacity. In the course of cytotoxic maintenance therapy, NK counts further declined, while TH and Treg cells increased, with lower proliferative potential of TH cells. We conclude that immunotherapeutic approaches in post-remission have to consider reduced NK cell function and further impairment of cellular immune responses during cytotoxic therapy. © 2014 Elsevier Ltd.

Loading Clinical Co Operation Group Immunotherapy at the Helmholtz Institute Munich collaborators
Loading Clinical Co Operation Group Immunotherapy at the Helmholtz Institute Munich collaborators